185 related articles for article (PubMed ID: 37775175)
21. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
Mallik S; Mallik G; Macabulos ST; Dorigo A
Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
[TBL] [Abstract][Full Text] [Related]
22. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
23. Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders.
Sargent JT; Smith OP
Br J Haematol; 2010 May; 149(4):465-77. PubMed ID: 20377591
[TBL] [Abstract][Full Text] [Related]
24. Immobilisation hypercalcaemia.
Mifsud S; Mifsud EL; Agius SM; Mula A; Gruppetta M
Br J Hosp Med (Lond); 2022 Jun; 83(6):1-7. PubMed ID: 35787163
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.
Wang R; Rajanayagam S; Ngan J; Renouf DA
Calcif Tissue Int; 2022 Oct; 111(4):391-395. PubMed ID: 35809111
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis and management of cancer associated hypercalcaemia.
Ralston SH
Cancer Surv; 1994; 21():179-96. PubMed ID: 8564993
[TBL] [Abstract][Full Text] [Related]
29. Refractory hypercalcemia of malignancy: a problem with many potential roots.
Farooki A
Front Endocrinol (Lausanne); 2023; 14():1088984. PubMed ID: 37265703
[TBL] [Abstract][Full Text] [Related]
30. Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Bassatne A; Murad MH; Piggott T; Drake MT; Rahme M; El-Hajj Fuleihan G
J Clin Endocrinol Metab; 2023 Feb; 108(3):563-584. PubMed ID: 36545699
[TBL] [Abstract][Full Text] [Related]
31. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
33. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
34. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
36. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
[TBL] [Abstract][Full Text] [Related]
37. Treatment of extreme hypercalcaemia: the role of haemodialysis.
Basok AB; Rogachev B; Haviv YS; Vorobiov M
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866671
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
39. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Adhikaree J; Newby Y; Sundar S
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
[No Abstract] [Full Text] [Related]
40. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M; Ishiguro H; Yano I; Toi M
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
